Grant: Collaborative Health Research Projects
McMaster University
$90,703.00
Development of a pumpless lung assist device which acts like an artificial placenta for neonates with respiratory failure.
EF 2013-14
Résumé
Respiratory failure is the major cause of morbidity among neonates with birth weights less than 1,500 g. Mechanicalventilation has dramatically improved neonatal outcome during the last decade. However, this approach is not effectiveenough in neonates with severe respiratory failure to prevent fatality or side-effects that lead to long-term impairment.Constructing a lung assist device (LAD) which imitates the placental gas exchange would be a milestone in innovation forneonatal medicine. Such a device would allow for additional gas exchange under end-stage lung failure when mechanicalventilation becomes inadequate. To create such a LAD we will combine and develop the following features: oxygenator withlow priming volume, the extracorporeal circulation only driven by the heart (pumpless), flow control and monitor, large borevascular access via umbilical vein and artery, hemocompatible inner surfaces (no activation of blood clotting) andeffectiveness for a body weight range of 0.5-5 kg. During the last 18 months we have formed an interdisciplinary researchgroup of physicians, engineers and students who have assisted in developing a LAD prototype as a stack of microfluidicoxygenators. Using a newborn hypoxic piglet model (n=6) we demonstrated the proof of principle. To develop inner surfacesof the LAD which do not activate blood clotting, we studied coating properties of the material using radiolabelling. To achievea large bore access we developed the design of an expandable catheter in collaboration with a medical technologycompany. This artificial placenta concept has been protected by filing a provisional US Patent, No. 61526288. The proposedLAD acting as an artificial placenta will be easy to install, cost effective and can be safely operated by standard neonatalintensive care personnel. The proposed LAD could become the next leading tool to aid infants with end-stage lung failure.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
446658-2013
Name nom
Fusch, Christoph
Department département
Pediatrics
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
90703
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Development of a pumpless lung assist device which acts like an artificial placenta for neonates with respiratory failure.
Keyword
NSERC
Application summary
Respiratory failure is the major cause of morbidity among neonates with birth weights less than 1,500 g. Mechanicalventilation has dramatically improved neonatal outcome during the last decade. However, this approach is not effectiveenough in neonates with severe respiratory failure to prevent fatality or side-effects that lead to long-term impairment.Constructing a lung assist device (LAD) which imitates the placental gas exchange would be a milestone in innovation forneonatal medicine. Such a device would allow for additional gas exchange under end-stage lung failure when mechanicalventilation becomes inadequate. To create such a LAD we will combine and develop the following features: oxygenator withlow priming volume, the extracorporeal circulation only driven by the heart (pumpless), flow control and monitor, large borevascular access via umbilical vein and artery, hemocompatible inner surfaces (no activation of blood clotting) andeffectiveness for a body weight range of 0.5-5 kg. During the last 18 months we have formed an interdisciplinary researchgroup of physicians, engineers and students who have assisted in developing a LAD prototype as a stack of microfluidicoxygenators. Using a newborn hypoxic piglet model (n=6) we demonstrated the proof of principle. To develop inner surfacesof the LAD which do not activate blood clotting, we studied coating properties of the material using radiolabelling. To achievea large bore access we developed the design of an expandable catheter in collaboration with a medical technologycompany. This artificial placenta concept has been protected by filing a provisional US Patent, No. 61526288. The proposedLAD acting as an artificial placenta will be easy to install, cost effective and can be safely operated by standard neonatalintensive care personnel. The proposed LAD could become the next leading tool to aid infants with end-stage lung failure.